1Department of Chemistry, Sathyabama Institute of Science & Technology, India
2, Chennai-600119, India
BibTex Citation Data :
@article{BCREC4469, author = {Birendra Mahato and T. Krithiga}, title = {Mesoporous ZnO/AlSBA-15 (7) Nanocomposite as An Efficient Catalyst for Synthesis of 3,4-dihydropyrimidin-2(1H)-one via Biginelli Reaction and Their Biological Activity Study}, journal = {Bulletin of Chemical Reaction Engineering & Catalysis}, volume = {14}, number = {3}, year = {2019}, keywords = {ZnO/AlSBA-15; Biginelli Reaction; Dihydropyrimidinone (DHPM); Antibacterial activity.}, abstract = { In this study, the mesoporous ZnO/AlSBA-15 (Si/Al=7) nanocomposite catalyst was prepared by using a combination of direct and impregnation procedure. The catalyst was characterized by X-ray diffraction (XRD), scanning electron microscope coupled with energy-dispersive x-ray spectroscopy (SEM-EDS), N 2 adsorption-desorption isotherm, Fourier transform infrared spectroscopy (FT-IR), and Temperature programmed reduction (TPR-H 2 ). The XRD and N 2 sorption results show the hexagonal mesoporous nature of catalyst with type IV adsorption isotherm. The surface area was calculated by the BET method and found to be 373 m 2 /g. From the TPR-H 2 study, the reducibility temperature of ZnO found to be 966 K. Further, the Biginelli reaction is a promising multi-component reaction in organic synthetic chemistry as it approaches the green chemistry protocols and adducts are extensively used as drugs, intermediate and in medicine. Hence, the catalytic activity was tested in one pot Biginelii reaction for the synthesis of 3,4-dihydropyrimidin-2(1H)-one's derivative. The product yield was observed to be 96% at temperature 333 K, at the short response time of 4 h. The two adducts were examined by 1 HNMR, 13 CNMR, and FT-IR spectroscopy. Besides, the biological activity of adduct (A) C 15 H 18 N 2 O 5 was explored by gram-positive bacteria (Staphylococcus aureus) and gram-negative microorganisms (E. coli). The adduct (A) C 15 H 18 N 2 O 5 shows a clear inhibition zone of 24 mm against E. Coli whereas Azithromycin shows an inhibition zone of 28 mm. Copyright © 2019 BCREC Group. All rights reserved }, issn = {1978-2993}, pages = {634--645} doi = {10.9767/bcrec.14.3.4469.634-645}, url = {https://ejournal2.undip.ac.id/index.php/bcrec/article/view/4469} }
Refworks Citation Data :
In this study, the mesoporous ZnO/AlSBA-15 (Si/Al=7) nanocomposite catalyst was prepared by using a combination of direct and impregnation procedure. The catalyst was characterized by X-ray diffraction (XRD), scanning electron microscope coupled with energy-dispersive x-ray spectroscopy (SEM-EDS), N2 adsorption-desorption isotherm, Fourier transform infrared spectroscopy (FT-IR), and Temperature programmed reduction (TPR-H2). The XRD and N2 sorption results show the hexagonal mesoporous nature of catalyst with type IV adsorption isotherm. The surface area was calculated by the BET method and found to be 373 m2/g. From the TPR-H2 study, the reducibility temperature of ZnO found to be 966 K. Further, the Biginelli reaction is a promising multi-component reaction in organic synthetic chemistry as it approaches the green chemistry protocols and adducts are extensively used as drugs, intermediate and in medicine. Hence, the catalytic activity was tested in one pot Biginelii reaction for the synthesis of 3,4-dihydropyrimidin-2(1H)-one's derivative. The product yield was observed to be 96% at temperature 333 K, at the short response time of 4 h. The two adducts were examined by 1HNMR, 13CNMR, and FT-IR spectroscopy. Besides, the biological activity of adduct (A) C15H18N2O5 was explored by gram-positive bacteria (Staphylococcus aureus) and gram-negative microorganisms (E. coli). The adduct (A) C15H18N2O5 shows a clear inhibition zone of 24 mm against E. Coli whereas Azithromycin shows an inhibition zone of 28 mm. Copyright © 2019 BCREC Group. All rights reserved
Article Metrics:
Last update:
In order for BCREC Group to publish and disseminate research articles, we need non-exclusive publishing rights (transfered from author(s) to publisher). This is determined by a publishing agreement between the Author(s) and BCREC Group. This agreement deals with the transfer or license of the copyright of publishing to BCREC Group, while Authors still retain significant rights to use and share their own published articles. BCREC Group supports the need for authors to share, disseminate and maximize the impact of their research and these rights, in any databases.
As a journal Author, you have rights for a large range of uses of your article, including use by your employing institute or company. These Author rights can be exercised without the need to obtain specific permission. Authors publishing in BCREC journals have wide rights to use their works for teaching and scholarly purposes without needing to seek permission, including:
Authors/Readers/Third Parties can copy and redistribute the material in any medium or format, as well as remix, transform, and build upon the material for any purpose, even commercially, but they must give appropriate credit (the name of the creator and attribution parties (authors detail information), a copyright notice, an open access license notice, a disclaimer notice, and a link to the material), provide a link to the license, and indicate if changes were made (Publisher indicates the modification of the material (if any) and retain an indication of previous modifications using a CrossMark Policy and information about Erratum-Corrigendum notification).
Authors/Readers/Third Parties can read, print and download, redistribute or republish the article (e.g. display in a repository), translate the article, download for text and data mining purposes, reuse portions or extracts from the article in other works, sell or re-use for commercial purposes, remix, transform, or build upon the material, they must distribute their contributions under the same license as the original Creative Commons Attribution-ShareAlike (CC BY-SA).
The Authors submitting a manuscript do so on the understanding that if accepted for publication, non-exclusive right for publishing (publishing right) of the article shall be assigned/transferred to Publisher of Bulletin of Chemical Reaction Engineering & Catalysis journal and Department of Chemical Engineering Diponegoro University/Masyarakat Katalis Indonesia - Indonesian Catalyst Society (MKICS) (or BCREC Group).
Upon acceptance of an article, authors will be asked to complete a 'Copyright Transfer Agreement for Publishing (CTAP)'. An e-mail will be sent to the Corresponding Author confirming receipt of the manuscript together with a 'Copyright Transfer Agreement for Publishing' form by online version of this agreement.
Bulletin of Chemical Reaction Engineering & Catalysis journal and Department of Chemical Engineering Diponegoro University/Masyarakat Katalis Indonesia-Indonesian Catalyst Society (MKICS), the Editors and the Advisory International Editorial Board make every effort to ensure that no wrong or misleading data, opinions or statements be published in the journal. In any way, the contents of the articles and advertisements published in the Bulletin of Chemical Reaction Engineering & Catalysis are sole and exclusive responsibility of their respective authors and advertisers.
Remember, even though we ask for a transfer of copyright for publishing (CTAP), our journal Author(s) retain (or are granted back) significant scholarly rights as mentioned before.
The Copyright Transfer Agreement for Publishing (CTAP) Form can be downloaded here: [Copyright Transfer Agreement for Publishing (CTAP) Form BCREC 2020]
The copyright form should be signed electronically and send to the Editorial Office in the form of original e-mail below: Prof. Dr. I. Istadi (Editor-in-Chief)Editorial Office of Bulletin of Chemical Reaction Engineering & CatalysisLaboratory of Plasma-Catalysis (R3.5), UPT Laboratorium Terpadu, Universitas DiponegoroJl. Prof. Soedarto, Semarang, Central Java, Indonesia 50275Telp/Whatsapp: +62-81-316426342E-mail: bcrec[at]live.undip.ac.id
(This policy statements has been updated at 24th December 2020)